E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2012 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/31/12Quest Diagnostics Sells OralDNA Labs to Access Genetics
MADISON, N.J., Dec. 31, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has sold substantially all of the assets of its OralDNA® Labs salivary-diagnostics business to Access Genetics, a leading clinical laboratory with advanced molecular diagnostics test development and information technology capabilities. Terms of the transaction were not disclosed. The divestiture of OralDNA represents a step i... 
Printer Friendly Version
12/04/12Quest Diagnostics Clinical Trials' Biorepository Accredited by the College of American Pathologists
Signifies achievement of highest quality standards for management of biological specimens and molecular material used in new drug development MADISON, N.J., Dec. 4, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that the specimen biorepository of its Quest Diagnostics Clinical Trials business, a leader in laboratory testing services to advance drug discovery and development, has been accredit... 
Printer Friendly Version
11/16/12Quest Diagnostics Details Strategy at 2012 Investor Day
-- Increases Invigorate Cost Reduction Goal by $100 Million to $600 Million -- -- Announces 76% Increase in Dividend to $1.20 per Share Annually -- MADISON, N.J., Nov. 16, 2012 /PRNewswire/ -- As previously announced, Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will host its Investor Day today, November 16, 2012 in New York City.  During the event, Quest Diagnostics executives will share their views of the industry and ... 
Printer Friendly Version
11/09/12Quest Diagnostics Confirms Investor Day on November 16
MADISON, N.J., Nov. 9, 2012 /PRNewswire/ -- As previously announced, Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will host an Investor Day on Friday, November 16, 2012 at The Hudson Theatre at the Millennium Broadway Times Square, 145 West 44th Street, New York, NY.  During the event, Quest Diagnostics' new executive leadership team will discuss the company's strategy, performance and plans to drive shareholder... 
Printer Friendly Version
10/19/12Quest Diagnostics Announces First EHRs Certified Under Laboratory-based Health IT Quality Solutions™ Program
Program designed to help facilitate rigorous industry-wide standards for quality and interoperability of physician-practice electronic health records with the company's laboratory data system MADISON, N.J., Oct. 19, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the first electronic health record (EHR) solutions to be certified under its Health IT Quality Solutions™ Program. The program is des... 
Printer Friendly Version
10/17/12Quest Diagnostics Reports Third Quarter 2012 Financial Results
-- Adjusted diluted EPS of $1.18, unchanged from prior year -- Reported diluted EPS of $1.01, 6% below prior year -- Revenues of $1.9 billion, 2.9% below prior year -- Full year adjusted EPS guidance of $4.45 - $4.55; revenue growth outlook of approximately 0.5% MADISON, N.J., Oct. 17, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the third quarter ended... 
Printer Friendly Version
10/16/12Quest Diagnostics to Acquire Clinical Outreach Laboratory from UMass Memorial Medical Center; Plan to Build 'Lab of the Future' to Serve Massachusetts Health Care Community
--Relationship will provide innovation, resources, and expanded access and connectivity for patients and doctors' offices, all at reduced costs-- MADISON, N.J. and WORCESTER, Mass., Oct. 16, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world leader in diagnostic testing, information and services, signed a definitive agreement today to purchase the clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care and the largest ... 
Printer Friendly Version
10/11/12Quest Diagnostics Launches New Organizational Structure To Drive Operational Excellence and Restore Growth; Appoints New Senior Leaders
MADISON, N.J., Oct. 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, launched a major management restructuring aimed at driving operational excellence and restoring growth. In addition, the company appointed senior leaders to head its new Commercial, Operations and Human Resources functions. The key element of the organization change will be to eliminate existing business structures and repl... 
Printer Friendly Version
10/09/12Focus Diagnostics and 3M Launch FDA-Cleared Simplexa™ Test on 3M™ Cycler for Molecular Influenza and Respiratory Virus Testing by Moderate Complexity Healthcare Facilities
First moderate-complexity Simplexa™ assay developed through funding by U.S. Department of Health and Human Services' BARDA BAA program for public health preparedness CYPRESS, Calif. and SAINT PAUL, Minn., Oct. 9, 2012 /PRNewswire/ -- Focus Diagnostics, a business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and 3M, a global diversified technology company (NYSE: MMM), today announced that the U.S. Food and Drug Administration... 
Printer Friendly Version
10/04/12Quest Diagnostics To Release Third Quarter 2012 Financial Results On October 17
MADISON, N.J., Oct. 4, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report third quarter 2012 results on Wednesday, October 17, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast availabl... 
Printer Friendly Version
10/02/12PLOS ONE Study Finds HIV Genotypic Sequencing Test Performs Comparably to Standard Phenotypic Test in Predicting Potential Response to CCR5 Antagonist
Genotypic HIV tropism laboratory-developed testing service now available nationally for HIV-infected patients MADISON, N.J., Oct. 2, 2012 /PRNewswire/ -- A laboratory-developed blood test that uses deep-sequencing technology performed comparably to the industry's standard phenotypic test in helping to predict potential clinical response to HIV-1 antiretroviral CCR5-antagonist therapy, according to a new study from researchers at Quest Diagnostics (NYSE: DGX) and Pfizer. The findings undersc... 
Printer Friendly Version
09/28/12Quest Diagnostics To Host Investor Day On November 16, 2012
MADISON, N.J., Sept. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the  world's leading provider of diagnostic testing, information and services, will host an investor day with institutional investors and sell-side financial analysts in New York City on Friday, November 16, 2012. During the event, Quest Diagnostics executives will discuss the company's strategy, performance and plans to drive shareholder value.   Advanced registration is required for ... 
Printer Friendly Version
09/14/12Quest Diagnostics Marks Ninth Year on Dow Jones Sustainability Index
MADISON, N.J., Sept. 14, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to the Dow Jones Sustainability World Index and North America Index. Quest Diagnostics is in its ninth year on the World Index (since 2004) and in its eighth on the North America Index (since 2005). "All of us at Quest Diagnostics are proud to have again earned a place on the Dow Jones Sustainability I... 
Printer Friendly Version
08/30/12Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Health's TERC Gene Marker
May enhance evaluation of cancer risk in the up to 1.5 million women who receive an indeterminate Pap test result each year MADISON, N.J., Aug. 30, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer. The test is designed to help physicians i... 
Printer Friendly Version
08/24/12Quest Diagnostics Gazelle® Mobile Health App Earns 2012 CIO 100 Award
MADISON, N.J., Aug. 24, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, accepted a 2012 CIO 100 award from International Data Group's (IDG) CIO magazine for its Gazelle® mobile health application. The 25th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology. The Gazelle mobile application for Blackberry... 
Printer Friendly Version
08/21/12Quest Diagnostics Blueprint for Wellness® Earns URAC's Comprehensive Wellness Accreditation
Endorsement recognizes wellness program for commitment to excellence MADISON, N.J., Aug. 21, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its Blueprint for Wellness® health risk assessment service earned Comprehensive Wellness Accreditation by meeting the highest standards for education, care and service delivery from URAC, a Washington, DC-based organization that establishes quality ... 
Printer Friendly Version
08/09/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 9, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on October 16, 2012, to shareholders of record of Quest Diagnostics common stock on October 1, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and se... 
Printer Friendly Version
07/27/12Harvard and MIT Students Rally Boston to Join Global Guinness World Record Attempt on World Hepatitis Day
Team HBV Chapters in Boston and Quest Diagnostics Urge City Residents and Visitors to Come Out and Be Counted at 'See No Evil, Hear No Evil, Speak No Evil' Viral Hepatitis Awareness Event, Boston Common, Noon Tomorrow BOSTON, July 27, 2012 /PRNewswire/ -- Students at Harvard and Massachusetts Institute of Technology aren't the type to take the summer off. Those who comprise a group called Team HBV, while working well-earned and prized internships, are also dedicating their off... 
Printer Friendly Version
07/19/12Quest Diagnostics Reports Second Quarter 2012 Financial Results
-- Adjusted diluted EPS of $1.17, up 4.5% -- Reported diluted EPS of $1.11, up 8.8% -- Revenues of $1.9 billion, essentially unchanged from prior year -- Full year adjusted earnings guidance unchanged; revenue growth outlook lowered to 1.0% - 2.0% MADISON, N.J., July 19, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the second quarter ended June 30, 2012, adjust... 
Printer Friendly Version
07/17/12Vitamin D Supplementation May Not Reduce Cholesterol-Related Heart Disease Risk, New Study Finds
Analysis published in Circulation by researchers at Quest Diagnostics and Rockefeller University contradicts prior research suggesting optimal vitamin D levels may have a beneficial impact on heart health MADISON, N.J., July 17, 2012 /PRNewswire/ -- Raising vitamin D to optimal from deficient blood levels may not improve total cholesterol and other blood lipids, key markers of cardiovascular disease risk, according to a study published today in Circulation, a publication of the American Hea... 
Printer Friendly Version
06/28/12National Business Group on Health Honors Quest Diagnostics as Platinum-Level Best Employer for Healthy Lifestyles
HealthyQuest Program Recognized for Eighth Straight Year MADISON, N.J., June 28, 2012 /PRNewswire/ -- The National Business Group on Health (NBGH) has honored Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, with its 2012 Best Employer for Healthy Lifestyles Award. This is the fourth consecutive year Quest Diagnostics has earned Platinum distinction, the highest level award, for its commitment to improving the health of employees a... 
Printer Friendly Version
06/27/12Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
MADISON, N.J., June 27, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report second quarter 2012 results on Thursday, July 19, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:00 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast availab... 
Printer Friendly Version
06/15/12Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
MADISON, N.J., June 15, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wells Fargo Securities 2012 Healthcare Conference in Boston.  The presentation is scheduled for Tuesday, June 19, 2012 at 9:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: http... 
Printer Friendly Version
06/01/12Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection
Results of a study of the test panel to be unveiled at the 2012 ASCO Annual Meeting on June 4; new test may reduce risk of surgical removal of healthy thyroids for some patients MADISON, N.J., June 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal. The test is believed... 
Printer Friendly Version
05/23/12Many Pregnant Women Not Screened For Chlamydia and Gonorrhea
Study by Quest Diagnostics of 1.3 million pregnant women also found that 16% of pregnant 16-year olds tested positive for chlamydia, higher than any other age group MADISON,  N.J., May 23, 2012 /PRNewswire/ -- Many women are not screened for chlamydia and gonorrhea infection during their pregnancy, and follow-up testing is not always performed as medically recommended for those who test positive for chlamydia, according to a study published online in the American Jou... 
Printer Friendly Version
05/17/12Quest Diagnostics Extends Endocrine Diagnostic Menu with New Congenital Adrenal Hyperplasia (CAH) Steroid Screening Panels
Features newborn screening panel that measures all 13 CAH-associated steroids by tandem mass spectrometry in a single analysis MADISON, N.J., May 17, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women. The p... 
Printer Friendly Version
05/16/12Quest Diagnostics Reminds Women to Make Their Health a Priority During National Women's Health Week
Company Distributes 10,000 Vouchers for Free Wellness Screenings in May in Support of American Cancer Society Choose You® Women's Health Movement MADISON, N.J., May 16, 2012 /PRNewswire/ -- This week, National Women's Health Week, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, joins the American Cancer Society Choose You® movement and the U.S. Department of Health and Human Services' (HHS) Office on Women's Health (OWH) in remind... 
Printer Friendly Version
05/11/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on July 18, 2012, to shareholders of record of Quest Diagnostics common stock on July 3, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and services... 
Printer Friendly Version
05/01/12Quest Diagnostics Sponsors American Cancer Society Choose You® Women's Health Movement
Company Offers 10,000 Vouchers for Free Wellness Screenings as National Presenting Sponsor NEW YORK, May 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced its national presenting sponsorship of the American Cancer Society Choose You® movement, which encourages women nationwide to live well today and stay well tomorrow. In support of the Choose You movement and in recognition of National Women'... 
Printer Friendly Version
04/27/12Three in Five Americans Misuse Their Prescription Drugs, Finds National Study of Prescription Medication Lab Testing
Quest Diagnostics Health Trends(TM) analysis finds many women and men of all ages, income levels and health plan coverage use pain and other prescription medications contrary to clinician orders, potentially putting their health at risk MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Results of a national study of nearly 76,000 laboratory tests for monitoring prescription drug use indicate that the majority of Americans tested misused their prescription drugs, including potentially ad... 
Printer Friendly Version
04/27/12Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced it has begun an effort to assign a unique Patient Identifier - a secure 16 digit identification number - to every Quest Diagnostics patient. In what is believed to be the largest effort of its kind in the area of assigning health IDs, the company has assigned unique identifiers to approximately 80 million Quest Diagnostics... 
Printer Friendly Version
04/25/12Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease)
The company's Athena Diagnostics business unit to unveil the new test at the American Academy of Neurology Annual Meeting this week in New Orleans MADISON, N.J. and WORCESTER, Mass., April 25, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new genetic testing service from its Athena Diagnostics business unit, a leader in neurology diagnostics, for amyotrophic lateral sclerosis (ALS),... 
Printer Friendly Version
04/18/12Quest Diagnostics Reports First Quarter 2012 Financial Results
-- Revenues of $1.9 billion, up 6.3% -- Adjusted diluted EPS of $1.07, up 7.0% -- Reported diluted EPS of $0.99 in 2012 compared to a loss of $0.33 per diluted share in 2011 -- Full year adjusted earnings outlook increased to $4.45 - $4.60 per diluted share MADISON, N.J., April 18, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the first quarter ended March 3... 
Printer Friendly Version
04/11/12Quest Diagnostics Names Steve Rusckowski as President and CEO
-- Daniel C. Stanzione, Ph.D. is appointed Non-Executive Chairman of the Board of Directors -- MADISON, N.J., April 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that Stephen H. Rusckowski will succeed Surya N. Mohapatra, Ph.D. as President and Chief Executive Officer, effective May 1, 2012. Dr. Mohapatra will remain in his role through April 30 to ensure a smooth leadership transition. Mr. Rusckowski will also become a member of the Board of Directors.... 
Printer Friendly Version
04/11/12FDA Clears the Quest Diagnostics Simplexa® C. difficile Molecular Test
Test eliminates nucleic-acid sample extraction, for faster results MADISON, N.J. and CYPRESS, Calif., April 11, 2012 /PRNewswire/ -- Quest Diagnostics  (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M™ Integrated Cycler.  The test, from the company's Focus Diagnostics business, is intended to ... 
Printer Friendly Version
04/09/12Institute for Health and Productivity Management Honors Quest Diagnostics
Company receives Level 1 Corporate Health and Productivity Award for its Commitment to Employee Health MADISON, N.J., April 9, 2012 /PRNewswire/ -- The Institute for Health and Productivity Management (IHPM) honored Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, with the Level 1 Corporate Health and Productivity Award earlier this month at its 12th annual conference in Orlando, Florida. "With its HealthyQuest employee wellnes... 
Printer Friendly Version
04/03/12Quest Diagnostics to Release First Quarter 2012 Financial Results
MADISON, N.J., April 3, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report first quarter 2012 results on Wednesday, April 18, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast available on Quest Diag... 
Printer Friendly Version
03/27/12Quest Diagnostics Supports 'Diabetes Alert Day'
Americans Encouraged to Use American Diabetes Association Diabetes Risk Test, and Take Action for Their Health MADISON, N.J., March 27, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today joins the American Diabetes Association (ADA) in recognizing the 24th annual Diabetes Alert Day. This one-day "wake-up call" encourages the public to take the Diabetes Risk Test to learn if they are at risk for developing T... 
Printer Friendly Version
03/22/12Redesigned Quest Diagnostics Website Features New Tools to Educate and Engage Healthcare Providers and Patients
MADISON, N.J., March 22, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has unveiled its redesigned corporate website at www.QuestDiagnostics.com. The site provides several new features, technologies and resources to help healthcare professionals and patients interact with the company online and access a broad span of information on diagnostic testing and health issues. The site features a new Test Center t... 
Printer Friendly Version
03/15/12Quest Diagnostics Launches First Molecular Test for Kidney Organ Transplant Rejection
Based on exclusive biomarker licenses with Beth Israel Deaconess Medical Center and Weill Cornell Medical College MADISON, N.J., March 15, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of the industry's first molecular blood test for identifying renal (kidney) organ-transplant rejection. The Renal Transplant Monitoring laboratory-developed test is designed to help physicians ... 
Printer Friendly Version
03/13/12Cocaine Positives Spike 33% After New Government Rule for Safety-Sensitive Workers
Amphetamines Positives Jump Nearly 26% After New Rule, Continuing Upward Trend, Shows Quest Diagnostics Drug Testing Index™ MADISON, N.J., March 13, 2012 /PRNewswire/ -- Safety-sensitive workers have been subject to more stringent government drug testing rules over the past year, and the crackdown may be paying off, according to annual Drug Testing Index™ data released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. New d... 
Printer Friendly Version
03/07/12Quest Diagnostics to Speak at the 2012 Barclays Capital Global Healthcare Conference
MADISON, N.J., March 7, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2012 Barclays Capital Global Healthcare Conference in Miami.  The presentation is scheduled for Wednesday, March 14, 2012 at 4:15 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: h... 
Printer Friendly Version
02/28/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on April 17, 2012, to shareholders of record of Quest Diagnostics common stock on April 3, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and servic... 
Printer Friendly Version
02/28/12Quest Diagnostics to Speak at the 2012 RBC Capital Markets Healthcare Conference
MADISON, N.J., Feb. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2012 RBC Capital Markets Healthcare Conference in New York City.  The presentation is scheduled for Wednesday, February 29, 2012 at 10:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following... 
Printer Friendly Version
02/23/12Care360® EHR From Quest Diagnostics Honored by Black Book's 2012 Rankings and Capterra's Top 20 List
EHR is Ideal Solution for Small to Medium-Sized Physician Practices Across the Nation LAS VEGAS, Feb. 23, 2012 /PRNewswire/ -- The highly-acclaimed Care360® Electronic Health Record (EHR) solution from Quest Diagnostics (NYSE: DGX) has been honored by receiving the top spot in the Single Physician Practice and ePrescribing categories in Black Book's 2012 Rankings of Top EHR and Electronic Medical Record (EMR) Vendors. In addition, Care360 EHR was ranked eighth on Capterra's To... 
Printer Friendly Version
02/22/12Trinity Health to Improve Revenue Cycle Through ChartMaxx® Implementation
Enterprise-Wide Content Management Helps Organization to Realize Greater Efficiencies Throughout the Continuum of Care LAS VEGAS, Feb. 22, 2012 /PRNewswire/ -- Trinity Health of Novi, Michigan, the fourth-largest Catholic healthcare system in the country, operating 49 acute-care hospitals, 379 outpatient facilities and 26 long-term care facilities throughout seven states, has selected Quest Diagnostics' (NYSE: DGX) ChartMaxx® Enterprise Content Management (ECM) solution to provide its staff... 
Printer Friendly Version
02/21/12Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs
Care360® EHR Streamlines the Development of Hospital Physician Referral Networks LAS VEGAS, Feb. 21, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, launched today at HIMSS the industry's first 30-day electronic health record (EHR) implementation guarantee for hospitals looking to quickly enable bi-directional data exchange with their ambulatory physicians through its award winning Care360® EHR we... 
Printer Friendly Version
01/24/12Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
-- Revenues of $1.9 billion, up 3% -- Adjusted diluted EPS of $1.23, up 19%; reported diluted EPS of $1.19, up 23% -- Cash flow from operations of $338 million compared to $340 million in 2010 -- 2012 guidance before special items: Diluted EPS between $4.40 and $4.55; revenues to grow between 2% and 2.5% -- Board approves $1 billion share repurchase authorization MADISON, N.J., Jan. 24, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), ... 
Printer Friendly Version
01/24/12Quest Diagnostics Increases Share Repurchase Authority by $1 Billion
-- Increase brings current authorization to $1.1 billion -- MADISON, N.J., Jan. 24, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $1 billion. This action increases the current share repurchase authorization to $1.1 billion. During 2011, the company repurchased approximately 17  million shares of co... 
Printer Friendly Version
01/20/12Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Based on exclusive collaboration with Biogen Idec, the test is only available in the U.S. through Quest Diagnostics' Focus Diagnostics lab MADISON, N.J., Jan. 20, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV(TM) Antibody ELISA testing service. STRATIFY JCV is the first b... 
Printer Friendly Version
01/20/12Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Based on exclusive collaboration with Biogen Idec, the test is only available in the U.S. through Quest Diagnostics' Focus Diagnostics lab MADISON, N.J., Jan. 20, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV™ Antibody ELISA testing service. STRATIFY JCV is the first blood test t... 
Printer Friendly Version
01/18/12Quest Diagnostics Launches National EHR Grant Program for Physicians
Program Offers Subsidies Equivalent to an 85 Percent Discount on Care360® EHR Physicians can receive a certified EHR solution for less than $100 per month MADISON, N.J., Jan. 18, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that, beginning January 23rd and throughout 2012, it is offering to eligible physician practices subsidies of 85 percent off the re... 
Printer Friendly Version
01/09/12ChartMaxx® Earns 2011 'Best in KLAS' for Healthcare Document Management and Imaging Software
Healthcare Professionals Honor MedPlus Enterprise-wide Electronic Patient Record System with Top Ranking for Eight of Last 10 Years CINCINNATI, Jan. 9, 2012 /PRNewswire/ -- MedPlus, the healthcare IT subsidiary of Quest Diagnostics (NYSE: DGX), announced today that its ChartMaxx® enterprise-wide electronic patient record system has been ranked the top healthcare Document Management and Imaging (DMI) software product, according to the 2011 Best in KLAS Awards: Software ... 
Printer Friendly Version
01/06/12Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
MADISON, N.J., Jan. 6, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its previously announced agreement with Lovelace Health System to acquire S.E.D. Medical Laboratories. Under the terms of the transaction, Quest Diagnostics has acquired the assets of S.E.D. Medical Laboratories and will manage in-patient labs for the four Lovelace ho... 
Printer Friendly Version
01/05/12Quest Diagnostics to Release Fourth Quarter and Full Year 2011 Financial Results
MADISON, N.J., Jan. 5, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report fourth quarter and full year 2011 results and provide financial guidance for 2012 on Tuesday, January 24, 2012 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the confere... 
Printer Friendly Version
01/04/12One in Six Pregnant Women Tested Are Positive for Hypothyroidism
Study of half a million pregnant women in the United States finds 15.5% of those tested were positive for gestational hypothyroidism, much higher than prior estimates MADISON, N.J., Jan. 4, 2012 /PRNewswire/ -- As many as one in six pregnant women tested were positive for gestational hypothyroidism, or underactive thyroid during pregnancy, under new clinical guidelines for detecting the disorder, according to a study published in The Journal of Clinical Endocrinology & M... 
Printer Friendly Version
01/03/12S.E.D. Labs to be Acquired by Quest Diagnostics
--Transaction will provide innovation, resources and expanded access and connectivity for patients-- --Synergistic lab purchase to enable Quest Diagnostics to significantly increase its presence in New Mexico-- ALBUQUERQUE, N.M. and MADISON, N.J., Jan. 3, 2012 /PRNewswire/ -- S.E.D. Medical Laboratories will soon become part of Quest Diagnostics Incorporated (NYSE: DGX), the world leader in diagnostic testing, information and services, through a definitive ag... 
Printer Friendly Version